Some smart people called analysts have different opinions about a company called Regeneron Pharmaceuticals. They think the company is worth different amounts of money, and they give their ideas numbers to show how much they think it's worth. Some say it could be worth more, some say it could be worth less. The people who own the company also have a chance to make bets on what will happen to the price of the company in the future. These are called options, and they can make more money if they guess right, but they can also lose money if they guess wrong. Some people want to know about these bets so they can decide if they should buy or sell parts of the company themselves. Read from source...

1. The title is misleading and does not reflect the content of the article. It implies that whales are betting on Regeneron Pharmaceuticals, but the article does not provide any evidence or data to support this claim. Whales are institutional investors who hold large positions in a stock, and their bets can have significant impacts on the market. However, the article does not mention which whales are involved or how much they are betting on Regeneron Pharmaceuticals.
2. The section "What The Experts Say On Regeneron Pharmaceuticals" is vague and unreliable. It only mentions two experts who released ratings on the stock, but does not provide any details or sources for their opinions. Moreover, it reports a wide range of target prices ($963.0 to $1076), which indicates a lack of consensus among analysts. The article also does not explain how these ratings are derived or what factors influence them. Furthermore, the article cites an upgrade from RBC Capital and a downgrade from Cantor Fitzgerald, but does not compare their performance or credibility in the past.
3. The section "Options are a riskier asset compared to just trading the stock" is irrelevant and confusing. It introduces options as a potential investment strategy for Regeneron Pharmaceuticals, but does not explain what options are or how they work. It also implies that options have higher profit potential than stocks, which may not be true depending on the market conditions and the underlying asset. The article then shifts to discussing serious options traders, who seem to have nothing to do with Regeneron Pharmaceuticals.
4. The section "If you want to stay updated on the latest options trades for Regeneron Pharmaceuticals" is a blatant advertisement for Benzinga Pro, which is not a reliable or objective source of information. It also does not provide any value or insight to readers who are interested in Regeneron Pharmaceuticals specifically, as it covers all the options trades for various stocks. The article then ends abruptly with a list of popular channels, press releases, tools, and features, which have nothing to do with the topic at hand.

- Regeneron Pharmaceuticals is a leading biotechnology company that develops and commercializes innovative medicines for various diseases, such as eye disorders, allergic asthma, and autoimmune diseases. The company also has a strong pipeline of potential drugs in clinical trials, including a COVID-19 antibody cocktail.